Volume 68, Issue 1, Pages (July 2015)

Slides:



Advertisements
Similar presentations
Volume 69, Issue 5, Pages (May 2016)
Advertisements

Volume 71, Issue 5, Pages (May 2017)
Volume 60, Issue 5, Pages (November 2011)
Volume 61, Issue 3, Pages (March 2012)
Volume 50, Issue 3, Pages (September 2006)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 4, Pages (October 2010)
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 53, Issue 4, Pages (April 2008)
Fred Saad  European Urology Supplements 
Volume 52, Issue 5, Pages (November 2007)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 64, Issue 4, Pages (October 2013)
Volume 69, Issue 1, Pages (January 2016)
Volume 51, Issue 4, Pages (April 2007)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Volume 68, Issue 1, Pages (July 2015)
Volume 52, Issue 3, Pages (September 2007)
Volume 63, Issue 6, Pages (June 2013)
Volume 68, Issue 4, Pages (October 2015)
Volume 63, Issue 2, Pages (February 2013)
Volume 65, Issue 5, Pages (May 2014)
Volume 74, Issue 1, Pages (July 2018)
Nomograms for Bladder Cancer
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 65, Issue 3, Pages (March 2014)
Volume 67, Issue 2, Pages (February 2015)
Volume 60, Issue 5, Pages (November 2011)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 54, Issue 5, Pages (November 2008)
Volume 66, Issue 5, Pages (November 2014)
Volume 73, Issue 6, Pages (June 2018)
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 4, Pages (April 2008)
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Volume 63, Issue 3, Pages (March 2013)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 5, Pages (November 2006)
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Prostate Cancer Nomograms: An Update
Volume 71, Issue 5, Pages (May 2017)
Volume 49, Issue 4, Pages (April 2006)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 74, Issue 3, Pages (September 2018)
PSA Levels and the Probability of Prostate Cancer on Biopsy
Volume 59, Issue 4, Pages (April 2011)
Volume 71, Issue 4, Pages (April 2017)
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
European Urology Oncology
Management of Prostate Cancer: Global Strategies
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Volume 74, Issue 6, Pages (December 2018)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Volume 54, Issue 1, Pages (July 2008)
Nomogram depicting estimates of postprogression survival, including estimates of 6-, 12-, and 24-month OS according to prechemotherapy and postchemotherapy.
Presentation transcript:

Volume 68, Issue 1, Pages 42-50 (July 2015) Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer  Karim Fizazi, Christophe Massard, Matthew Smith, Michael Rader, Janet Brown, Piotr Milecki, Neal Shore, Stephane Oudard, Lawrence Karsh, Michael Carducci, Ronaldo Damião, Huei Wang, Wendy Ying, Carsten Goessl  European Urology  Volume 68, Issue 1, Pages 42-50 (July 2015) DOI: 10.1016/j.eururo.2014.10.001 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Univariate analyses of bone-specific factors. (A) Alkaline phosphatase (ALP ≤ median [143 U/l] vs > median). (B) Bone-specific alkaline phosphatase (BSAP <146 U/l vs ≥146 U/l). (C) Urinary N-telopeptide (uNTx ≤50 nmol/mmol vs >50 nmol/mmol). (D) Previous skeletal related event (SRE; no vs yes). (E) Worst pain absent or mild (Brief Pain Inventory—Short Form [BPI-SF] score ≤4 vs >4). European Urology 2015 68, 42-50DOI: (10.1016/j.eururo.2014.10.001) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Univariate analyses of disease characteristics and laboratory values. (A) Prostate-specific antigen (PSA; <10 ng/ml vs ≥10 ng/ml). (B) Presence of visceral metastases (no vs yes). (C) Eastern Co-operative Oncology Group (ECOG) performance status (≤1 vs 2). (D) Hemoglobin (≤median [128g/l] vs >median). European Urology 2015 68, 42-50DOI: (10.1016/j.eururo.2014.10.001) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Ten variable nomograms for the prediction of 12-mo and 24-mo overall survival probability and median overall survival in months. To use this nomogram, complete the following steps: 1. Identify the scale for the first variable and draw a vertical line at the value until it intersects the “Points” axis; read off the corresponding risk score (points) for that variable. 2. Repeat this process for each variable. 3. Calculate the total risk score, that is, the sum of the points for each variable. 4. Locate the total risk score on the “Total points” axis and draw a vertical line downwards to identify the predicted survival probabilities. aIn one patient, the diagnosis of bone metastases occurred months before diagnosis of the primary tumor. European Urology 2015 68, 42-50DOI: (10.1016/j.eururo.2014.10.001) Copyright © 2014 European Association of Urology Terms and Conditions